Life Sciences

An evolving regulatory landscape, along with a continuing wave of M&A activity, is transforming the life sciences industry. Navigating a path to growth during this era of transformation presents complex challenges for industry leaders and start-ups, as well as their investors and capital providers. We can help.

Latest Insights, News, and Events

Latest Insights, News, and Events

Client Successes

Guided Supernus Pharmaceuticals and Galderma Laboratories to victory in the first-ever successful defense of a pharmaceutical patent in an inter partes review

Secured a trial win for Helsinn Healthcare in the first district court interpretation of the scope of the on-sale bar following the America Invents Act

Serve as lead counsel to a global pharmaceutical company across four continents in high-profile government investigations and internal reviews

Advised Merck & Co. on major cross-border M&A transactions including its strategic agreement with Quartet Medicine and its US$1.25B acquisition of Afferent Pharmaceuticals

A Recognized Leader

We bring a global, interdisciplinary approach to support our life sciences clients’ complex, often mission-critical needs – from structuring transactions, to protecting critical intellectual property, to resolving complicated U.S. healthcare and global anti-corruption enforcement matters, to providing the savvy compliance and legal counsel that keeps business moving forward.

We advise seven of the 10 largest global pharmaceutical companies, as well as numerous emerging companies, and the investors and financial institutions that help bring their innovative ideas to life in markets across Asia, Europe, Latin America, and the United States. 


  • Our global team of 200+ life sciences lawyers includes former researchers, executives, and in-house counsel from leading life sciences companies.
  • We bring creative thinking to everything we do—from devising innovative strategies for getting deals done to proactively partnering with clients on compliance reviews to reduce anticorruption risks in jurisdictions around the world.
  • We advise life sciences companies on all aspects of anti-corruption law: conducting global risk assessments; leading internal investigations and negotiating with the DOJ, SEC, and foreign prosecutors; designing and enhancing compliance programs; overseeing due diligence in transactions; and negotiating debarment and related sanctions with the US government, World Bank, and other development banks.
  • Our lawyers represent the largest life sciences companies in complex domestic and international matters. We have secured a long string of litigation victories on behalf of our clients, including success in numerous bet-the-company patent litigations and post-grant proceedings.


  • Named a Life Sciences Group of the Year by Law360.
  • Recognized as “one of the best pharmaceutical patent litigation outfits in the world” in the IAM Patent Litigation 1000.
  • Chair of our Life Sciences practice, Bruce Wexler was named Transatlantic Lawyer of the Year – IP by The American Lawyer.
  • Partner David Shine was named a Dealmaker of the Year by The American Lawyer for his work advising Merck on the US$14.2B sale of its consumer care business.
  • Pharmaceutical Team of the Year by Intellectual Property Magazine.
  • Most Valuable Players – Life Sciences and IP by Law360.
  • Winner of Four Awards by LMG Life Sciences including General Patent Litigator of the Year (New York), Post Grant Proceedings Attorney of the Year, and Two Impact Hatch-Waxman Cases of the Year.